Related Experiment Video
Updated: Jul 9, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
CD200: a putative therapeutic target in cancer
Jérôme Moreaux1, Jean Luc Veyrune, Thierry Reme
1CHU Montpellier, Hopital St Eloi, Institut de Recherches en Biothérapie, Av Augustin Fliche, 34285 Montpellier Cedex 5, France.
Biochemical and Biophysical Research Communications
|December 7, 2007
Summary
CD200, a protein involved in immune regulation, is overexpressed in many cancers, including renal and colon carcinoma. This finding suggests CD200 may serve as a potential therapeutic target and prognostic factor for various malignancies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- CD200 is a membrane glycoprotein known for its immunoregulatory role, suppressing T-cell responses via CD200R.
- Recent findings highlight CD200 as a prognostic factor in multiple myeloma and acute myeloid leukemia.
Purpose of the Study:
- To investigate the expression of CD200 across a broad spectrum of human cancers.
- To evaluate CD200 as a potential prognostic marker and therapeutic target in malignancies.
Main Methods:
- Utilized publicly available gene expression datasets from Oncomine, Amazonia, and ITTACA databases.
- Analyzed CD200 gene expression in normal versus malignant human tissues and cell lines.
Main Results:
- Significant CD200 overexpression was observed in renal carcinoma, head and neck carcinoma, testicular cancer, malignant mesothelioma, colon carcinoma, MGUS/smoldering myeloma, and chronic lymphocytic leukemia.
- CD200 expression levels correlated with tumor progression in several cancer types.
Conclusions:
- The data indicate that CD200 is frequently overexpressed in various cancers.
- CD200 represents a promising therapeutic target and prognostic biomarker for a wide range of malignancies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...